VERQUVO®

(vericiguat) tablets 2.5 mg, 5 mg, 10 mg

Patient Profiles

Bernard, age 70, male

View the Profile of a Patient Diagnosed With Chronic Heart Failure and Experienced a Second HF Hospitalization 3 Weeks Ago

*Not actual patient

Has worsening chronic heart failure (HF) and just experienced a second HF-related hospitalization

Diagnosed 6 months ago with chronic HF after his first hospitalization

  • New York Heart Association (NYHA) class III heart failure
  • Left ventricular ejection fraction (LVEF) 28%
  • Started on sacubitril/valsartan

Experienced another HF hospitalization 3 weeks ago

  • NT-proBNP levels while hospitalized: 3,913 pg/mL

Comorbidities:

  • Controlled Hypertension
  • Hypercholesterolemia
  • eGFR =45 mL/min/1.73 m2

Medications:

  • Sacubitril/valsartan
  • Carvedilol
  • Rosuvastatin
  • Furosemide

Activity level:

  • Finds it hard to do light activity such as grocery shopping and walking short distances

eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal prohormone B-type natriuretic peptide.

Indications and Usage

VERQUVO is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

Selected Safety Information

WARNING: EMBRYO-FETAL TOXICITY

Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.

  • VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.

  • VERQUVO is contraindicated in pregnancy.

  • Embryo-Fetal Toxicity: Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.

  • In a clinical trial, the most commonly observed adverse events with VERQUVO vs placebo, occurring at a frequency ≥5%, were hypotension (16% vs 15%) and anemia (10% vs 7%).

  • Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended due to the potential for hypotension.

  • There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.

Before prescribing VERQUVO, please read the accompanying Prescribing Information, including the Boxed Warning about embryo-fetal toxicity. The Medication Guide also is available.

US-VER-0126810/21